Friday, March 19, 2010
Note: genes/disease relevance/links to further information
BRCA2 breast cancer 2, early onset 13q12.3
* Breast-ovarian cancer, familial, 2
* Fanconi anemia, complementation group D1
* Prostate cancer
* Breast cancer, male, susceptibility to
* Wilms tumor
* Pre-B-cell acute lymphoblastic leukemia
* Pancreatic cancer
MSH2 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 2p22-p21
* Colorectal cancer, hereditary nonpolyposis, type 1
* Muir-Torre syndrome
* Mismatch repair cancer syndrome
Medical News: SGO: New Option for Recurrent Ovarian Cancer? - in "Carboplatin-PLD" Meeting Coverage, SGO
Source reference: Pujade-Lauraine E, et al "Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin in patients with platinum-sensitive ovarian cancer in late relapse" SGO 2010; Abstract SAS 2
Translational research in the Gynecologic Oncology Group: Evaluation of ovarian cancer markers, profiles, and novel therapies.
The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases.
"BRCAPRO version 5.0 can be particularly useful in dealing with non-familial MBC, a circumstance that often represents a challenging situation in genetic counseling."
AUTHORS' CONCLUSIONS: We are unable to make any evidence-based recommendations as we found no comparative studies assessing the effectiveness of tamoxifen in women with recurrent ovarian cancer. There is limited evidence on anti-tumour activity from phase 2 studies, but these contain no data on the effect of tamoxifen on symptom control, QOL or the prolongation of life.
Plain language summary
No evidence to suggest tamoxifen benefits patients with relapsed ovarian cancer
Ovarian cancer often spreads before symptoms show. Cytotoxic drugs are often only partly effective and cause severe side-effects. The main aims of treatment for relapsed disease are symptom control and prolongation of life. No data from RCTs or non-RCTs were found, so there was no evidence that tamoxifen was effective and safe as a treatment for relapsed ovarian cancer. Laboratory studies suggest tamoxifen may be effective as a treatment for women with ovarian cancer. Although, uncontrolled non-comparative trials on patients with relapsed ovarian cancer showed tamoxifen may shrink or stabilise tumours in a small number, there is a strong need for an RCT or good quality non-randomised comparative studies to determine the effectiveness and safety of tamoxifen in terms of overall survival, tumour response, symptom control, quality of life and adverse events.
"The researchers concluded that temsirolimus may have modest cytostatic activity in patients with prior chemotherapy and should be investigated further. Dr. Behbakht suggested that the agent might be combined with bevacizumab for increased activity and is already being studied in combination with paclitaxel. He noted that isolation, enumeration, and characterisation of CTCs from patients should also be investigated in further trials."
News - Bevacizumab Plus Docetaxel Shows Promise for Ovarian Cancer, No Surprising Toxicities: Presented at SGO
"...The clinical trials will use Agendia's MammaPrint test and TargetPrint Her2 risk scores, as well as estrogen receptor and progesterone receptor status information and MRI to help determine eligibility for the trial.
The large-scale trial will involve more than twenty university hospitals and medical centers spread around the country, including The University of Texas MD Anderson Cancer Center, the Mayo Clinic in Arizona and Minnesota, the Fred Hutchinson Cancer Research Center, and a number of others...."
NIH Plans Genetic Testing Registry
March 18, 2010
"NEW YORK (GenomeWeb News) – The National Institutes of Health is starting a public database on genetic testing that will allow consumers, researchers, health care providers, and others search through information submitted by genetic test providers, NIH said today....The GTR, which is expected to be available in 2011, will be overseen by NIH's Office of the Director, and its development will be handled by the National Center for Biotechnology Information."
MRI for breast cancer: who benefits, who is harmed? Cancer World - Education & knowledge through people & facts
full access: Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance - U of T
The results of this research provide pre-clinical data to warrant further evaluation of statins as potential anti-cancer agents to treat ovarian carcinoma. Many statins are inexpensive, off-patent generic drugs that are immediately available for use as anti-cancer agents. We provide evidence that lovastatin triggers apoptosis of ovarian cancer cells as a single agent by a mevalonate-dependent mechanism. Moreover, we also show lovastatin synergizes with doxorubicin, an agent administered for recurrent disease. This synergy occurs by a novel mevalonate-independent mechanism that antagonizes drug resistance, likely by inhibiting P-glycoprotein. These data raise important issues that may impact how statins can best be included in chemotherapy regimens.